The development of combretastatin A4 phosphate as a vascular targeting agent.
about
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Antivascular ultrasound therapy extends survival of mice with implanted melanomasTechnology insight: water diffusion MRI--a potential new biomarker of response to cancer therapy.Tumor vascular changes mediated by inhibition of oncogenic signaling.18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.An overview of translational (radio)pharmaceutical research related to certain oncological and non-oncological applications.The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents.Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments.Synthesis and biological evaluation of benzo[b]furans as inhibitors of tubulin polymerization and inducers of apoptosis.Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.Vascular targeting agents.Serial monitoring of human systemic and xenograft models of leukemia using a novel vascular disrupting agent.Biological Characterization of an Improved Pyrrole-Based Colchicine Site Agent Identified through Structure-Based DesignEffects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI.Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.Solid Tumor Therapy Using a Cannon and Pawn Combination Strategy.Selective targeting of the tumour vasculature.The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse HepatocarcinomaDisrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.Tubulin inhibitors: a patent review.Combretastatin A4-phosphate and its potential in veterinary oncology: a review.Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice.Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo.Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interfaceEffects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels.B-ring-modified isocombretastatin A-4 analogues endowed with interesting anticancer activities.Radiotherapy in combination with vascular-targeted therapies.A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.Drug resistance reversal by combretastatin-A4 phosphate loaded with doxorubicin in polymersomes independent of angiogenesis effect.Biological evaluation of benzosuberones.The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization.The vascular disrupting agent ombrabulin (AVE8062) enhances the efficacy of standard therapies in head and neck squamous cell carcinoma xenograft models.Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer.
P2860
Q26781365-268B4FEA-E571-4259-B899-F8D172A0901CQ30475723-F719D01D-FA00-4E20-9865-4E7B2A0B5774Q31147727-DA5F2497-D046-436A-B4DF-6DDD95FFD4C0Q33671385-22459B4E-7035-4FD9-8D47-358F88A63724Q33820595-38F98FC1-E403-4254-A4BB-92E35B3032F2Q33921024-F8EBE0DC-8455-4635-92CF-8C5182A74EE9Q34093032-A96EBF64-1FC2-4DF7-A93E-1A78C75C1D70Q34122191-A255828D-3210-4020-9231-90F9B266C3C7Q34478450-41B47B40-DDFC-479D-884C-1E62C351A8B8Q35033930-D021DD65-85AC-479F-9938-CEF6C2A27981Q35148206-AC6643DB-7C73-4101-99BB-949556B11EA7Q35642613-E913CEA6-2868-4BB8-9114-6F9DB9FA7AF0Q36225973-821D8466-375A-4497-ABA6-5AF682B32C4FQ36502953-4F32F134-3AFC-467B-84C2-9830F1BE46F1Q36615531-84C0927A-7F27-4A1A-8FF2-C0D2F6268AB2Q36822093-72C5F3BE-28AA-484C-97BD-422CD89E5081Q36926018-4F44A8B1-3DD0-4A98-9DC0-2D31D8DF8023Q37311351-02B12DDF-4A0A-43A0-8218-BBDD6CBA2E9DQ37528662-E06A4589-C90A-4A49-ABB3-4CF33B714998Q37694429-65667013-D11C-4BF8-AD2F-B452B01B2057Q38169237-43145E6E-8F88-48CF-82F2-9CD84DB09EE0Q38490875-7CB4FE34-FB67-4987-8678-132E7EF4BD1EQ38581959-2D2390E9-90A4-4982-AAE8-449940A40D0FQ38869295-3ECB71A8-FFB8-4AA5-AF1B-DF1A4AF45018Q38881452-C71B1B23-55B9-4C22-898B-1E7205503560Q38979348-E64D200A-16C6-48D4-AAD6-1B0A1121615DQ39010651-46AB734A-E2E9-4A35-9192-73A261E86717Q39459714-AA0DD67B-92CB-4B32-8DD4-B17C74958F07Q42203737-4FB5CF39-B9B6-48A9-8B05-30B4B608EFECQ43898245-8A2D38AE-159C-4926-A211-2AC2B191EDBFQ46380343-7D10A4D6-D5AE-44EF-B7E4-2BF84BB07871Q46533210-8B7EB766-48AB-4910-8AD6-5CF5E0EC595BQ46882346-B83F3DE9-3059-401A-8670-7649AD575226Q52627703-E296806B-ACF4-4739-85E1-820145C421D7Q54479575-5852A14B-E8E0-479F-9B37-2B2A1F569485
P2860
The development of combretastatin A4 phosphate as a vascular targeting agent.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The development of combretastatin A4 phosphate as a vascular targeting agent.
@ast
The development of combretastatin A4 phosphate as a vascular targeting agent.
@en
type
label
The development of combretastatin A4 phosphate as a vascular targeting agent.
@ast
The development of combretastatin A4 phosphate as a vascular targeting agent.
@en
prefLabel
The development of combretastatin A4 phosphate as a vascular targeting agent.
@ast
The development of combretastatin A4 phosphate as a vascular targeting agent.
@en
P1476
The development of combretastatin A4 phosphate as a vascular targeting agent.
@en
P2093
David J Chaplin
Sally A Hill
P304
P356
10.1016/S0360-3016(02)03924-X
P407
P577
2002-12-01T00:00:00Z